Completion of Investment

8th Apr 2009 18:21

For Immediate release: 8 April 2009

Imperial Innovations Group plc ("Imperial Innovations" or the "Company") Completion of £2.5m investment in portfolio company Veryan

Further to the announcement of 2 April 2009 concerning the Company's investment in Veryan Holdings Ltd, Imperial Innovations is pleased to confirm that this investment has now been completed.

For further information please contact:

Imperial Innovations

Susan Searle, Chief Executive

Diana Crisp, PR ManagerTel. +44 (0)20 7594 6589M:Communications

Patrick d'Ancona or Ben Simons

Tel. +44 (0)20 7153 1540

J.P. Morgan Cazenove (NOMAD to Imperial Innovations)

Steve BaldwinTel. +44(0)20 7588 2828About Imperial Innovations

Imperial Innovations is one of the UK's leading technology commercialisation and investment companies. Founded in 1986 and admitted to the AIM Market of the London Stock Exchange in 2006, Imperial Innovations' access to early stage technology and intellectual property is unparalleled. Imperial Innovations' integrated commercialisation approach encompasses the identification of ideas, the protection of intellectual property, the development and licensing of technology and the formation, incubation and funding, through investment, of technology businesses.

Based at Imperial College London, Imperial Innovations' portfolio of equity holdings in more than 80 companies spans across its four core areas of Healthcare, Engineering, Energy & Environment and Software & IT.

Companies in the portfolio include: Nexeon (lithium ion battery technology), Circassia (allergy therapeutics), Polytherics (drug development), Evo Electric (electric motor and generator solutions), Respivert (respiratory drug development), Quantasol (solar concentrators) and Inforsense (business analytics)

Imperial Innovations has already realised significant value from its investments to date including from a recent trade sale in December 2008 when Thiakis Limited, a company in which Imperial Innovations had a 23.7% stake, was sold for up to £100 million to US-based Wyeth Pharmaceuticals.

www.imperialinnovations.co.uk

vendor

---

Related Shares:

Imperial Innovations Group